Federal Maritime Commission, Washington, D.C. 20573.

Worldwide Forwarding Company, 3846 Ingraham St., #402, Los Angeles, CA 90005, David Chun, Sole Proprietor

Dependable Auto Shippers Inc. of Texas, 9208 Forney Road, Dallas, TX 75227, Officer: Frederick A. London, President

AIMAR USA, INC., 8437 N.W. 72nd Street, Miami, FL 33166, Officers: Goffredo R. Holbik, President, Pablo Miguel Olaya, Vice President

Dated: March 13, 1998.

Joseph C. Polking,

Secretary.

[FR Doc. 98–6965 Filed 3–17–98; 8:45 am]

BILLING CODE 6730–01–M

FEDERAL RESERVE SYSTEM

Formations of, Acquisitions by, and Mergers of Bank Holding Companies

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 *et seq.*) (BHC Act), Regulation Y (12 CFR Part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The application also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act. Unless otherwise noted, nonbanking activities will be conducted throughout the United States.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than April 10, 1998.

A. Federal Reserve Bank of Cleveland (Paul Kaboth, Banking Supervisor) 1455 East Sixth Street, Cleveland, Ohio 44101-2566:

1. Portage Banc Shares, Inc., Ravenna, Ohio; to become a bank holding company by acquiring 100 percent of the voting shares of Portage Community Bank, Ravenna, Ohio, a *de novo* bank.

B. Federal Reserve Bank of San Francisco (Maria Villanueva, Manager of Analytical Support, Consumer Regulation Group) 101 Market Street, San Francisco, California 94105-1579:

1. Security Bank Holding Company, Coos Bay, Oregon; to acquire 100 percent of the voting shares of Family Security Bank, Brookings, Oregon (in organization).

Board of Governors of the Federal Reserve System, March 12, 1998.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 98–6914 Filed 3–17–98; 8:45 am]

BILLING CODE 6210–01–F

FEDERAL RESERVE SYSTEM

Sunshine Act Meeting

TIME AND DATE: 11:00 a.m., Monday, March 23, 1998.

PLACE: Marriner S. Eccles Federal Reserve Board Building, 20th and C Streets, N.W., Washington, D.C. 20551.

STATUS: Closed.

MATTERS TO BE CONSIDERED:

1. Proposed leasing of space within the Federal Reserve System.

2. Personnel actions (appointments, promotions, assignments, reassignments, and salary actions) involving individual Federal Reserve System employees.

3. Any items carried forward from a previously announced meeting.

CONTACT PERSON FOR MORE INFORMATION: Joseph R. Coyne, Assistant to the Board; 202–452–3204.

SUPPLEMENTARY INFORMATION: You may call 202–452–3206 beginning at approximately 5 p.m. two business days before the meeting for a recorded announcement of bank and bank holding company applications scheduled for the meeting; or you may contact the Board's Web site at http://www.bog.frb.fed.us for an electronic announcement that not only lists applications, but also indicates procedural and other information about the meeting.

Dated: March 13, 1998.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 98–7060 Filed 3–13–98; 4:19 pm]

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Office of Minority Health; Availability of Funds for Grants for the Bilingual/Bicultural Service Demonstration Grant Program

AGENCY: Office of the Secretary, Office of Public Health and Science, Office of Minority Health.

ACTION: Correction.

SUMMARY: On March 2, 1998 (63 FR 10226), OMH published a notice announcing the Availability of Funds for Grants for the Bilingual/Bicultural Service Demonstration Grant Program. This notice corrects the application receipt date which appeared in that notice, FR Doc. 98–5233, on page 10227. Under the Deadline Section in the second column, it stated that ''grant applications must be received by the OMH Grants Management Office 60 days after date of publication or by April 13, 1998.'' This is corrected to read ''grant applications must be received by the OMH Grants Management Office by May 1, 1998.''

Dated: March 12, 1998.

Clay E. Simpson, Jr.,

Deputy Assistant Secretary for Minority Health.

[FR Doc. 98–6980 Filed 3–17–98; 8:45 am]

BILLING CODE 4160–17–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 98N–0147]

Agency Information Collection Activities: Proposed Collection; Survey of Mammography Facilities; Comment Request

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing an opportunity for public comment on the proposed collection of certain information by the agency. Under the Paperwork Reduction Act of 1995 (the PRA), Federal agencies are required to publish notice in the **Federal Register**

concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on a voluntary survey of mammography facilities to assess the impact of the Mammography Quality Standards Act (the MQSA) on access to mammography services.

DATES: Submit written comments on the collection of information by May 18, 1998.

ADDRESSES: Submit written comments on the collection of information to the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857. All comments should be identified with the docket number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT: Margaret R. Schlosburg, Office of Information Resources Management (HFA–250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–1223.

SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501–3520), Federal agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. ''Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes agency requests or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) requires Federal agencies to provide a 60-day notice in the **Federal Register** concerning each proposed collection of information, including each proposed extension of an existing collection of information, before submitting the collection to OMB for approval. To comply with this requirement, FDA is publishing notice of the proposed collection of information listed below.

With respect to the following collection of information, FDA invites comments on: (1) Whether the proposed collection of information is necessary for the proper performance of FDA's functions, including whether the information will have practical utility; (2) the accuracy of FDA's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques, when appropriate, and other forms of information technology.

Access to Mammography Services Survey—New

Under the MQSA (42 U.S.C. 2636), FDA is authorized to develop regulations, inspect facilities, and ensure compliance with standards established to assure quality mammography services for all women. In the legislative history of the MQSA, Congress expressed the need to balance quality improvements with impact on access to mammography services. The General Accounting Office has recently done an assessment and concluded that access has been minimally affected. However, new regulations will become effective April 28, 1999 and October 28, 2002.

The Mammography Facility Survey will provide FDA with important information about the impact of specific aspects of the MQSA program on access to mammography services. The survey will provide facility closure rates both pre- and post-implementation of the final regulations. Furthermore, the Survey will determine reasons for facility closures, including those related to specific MQSA regulations and those that are attributable to general operational challenges. Finally, the Survey will also gather information from operating facilities to determine the impact of MQSA regulations on facilities that continue to provide mammography services. Participation will be voluntary. A total of 120 facilities that have ceased to provide mammography services will be given the opportunity to take part in a 15-minute telephone survey. These facilities will be matched by zipcode to 480 open mammography centers to provide up to four controls for each closed facility . Each of the open facilities will also be offered the opportunity to participate in the study until we have two matched controls. The Survey will collect demographic information from each survey respondent, and then ask questions that address the perceived impact on the facility's ability to provide mammography services of factors related to specific MQSA regulations, as well as factors not directly associated with MQSA requirements. Additional descriptive information about the facilities will be abstracted from various FDA data bases in order to enhance the level of detail that is known about each respondent.

FDA estimates the burden of this collection of information as follows:

TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN[1]

No. of Respondents	Annual Frequency per Response	Total Annual Responses	Hours per Response	Total Hours
720	1	720	0.25	180

[1]There are no capital costs or operating and maintenance costs associated with this collection of information.

Dated: March 8, 1998.

William K. Hubbard,

Associate Commissioner for Policy Coordination.

[FR Doc. 98–6906 Filed 3–17–98; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 98N–0148]

International Drug Scheduling; Convention on Psychotropic Substances; Dihydroetorphine; Ephedrine; Remifentanil; Isomers of Psychotropic Substances

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is requesting interested persons to submit data or comments concerning abuse potential, actual abuse, medical usefulness, and trafficking of three drug substances. This information will be considered in preparing a response from the United States to the World Health Organization (WHO) regarding abuse liability, actual abuse, and trafficking of these drugs. WHO will use this information to consider whether to recommend that certain international restrictions be placed on these drugs. This notice requesting information is required by the Controlled Substances Act (CSA).

DATES: Submit written comments by April 17, 1998.

ADDRESSES: Submit written comments to the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Nicholas P. Reuter, Office of Health Affairs (HFY–20), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–1696, E–mail: NReuter@bangate.FDA.gov.

SUPPLEMENTARY INFORMATION: The United States is a party to the 1971 Convention on Psychotropic Substances. Article 2 of the Convention on Psychotropic Substances provides that if a party to that convention or WHO has information about a substance, which in its opinion may require international control or change in such control, it shall so notify the Secretary General of the United Nations and provide the Secretary General with information in support of its opinion.

The CSA (21 U.S.C. 811 *et seq.*) (Title II of the Comprehensive Drug Abuse Prevention and Control Act of 1970) provides that when WHO notifies the United States under Article 2 of the Convention on Psychotropic Substances that it has information that may justify adding a drug or other substance to one of the schedules of that convention, transferring a drug or substance from one schedule to another, or deleting it from the schedules, the Secretary of State must transmit the notice to the Secretary of Health and Human Services (the Secretary of HHS). The Secretary of HHS must then publish the notice in the **Federal Register** and provide opportunity for interested persons to submit comments to assist HHS in preparing scientific and medical evaluations about the drug or substance. The Secretary of HHS received the following notices from WHO:

I. WHO Notification

Ref. : C. L.23 .1997

WHO questionnaire for collection of information for review of dependence-producing psychoactive substances

The Director-General of the World Health Organization presents his compliments and has the pleasure of informing Member States that the Thirty-first Expert Committee on Drug Dependence will meet from 23 to 26 June 1998 to review the following substances:

1. Dihydroetorphine
2. Ephedrine
3. Remifentanil
4. With regard to all substances in Schedules I and II of the Convention on Psychotropic Substances, 1971:

(a) their isomers, except where expressly excluded, whenever the existence of such isomers is possible;

(b) their esters and ethers, except where included in another schedule, whenever the existence of such esters and ethers is possible;

(c) salts of those esters, ethers and isomers, under the conditions stated above, whenever the formation of such salts is possible;

(d) a substance resulting from modification of the chemical structure of a substance already in these schedules and which produces pharmacological effects similar to those produced by the original substance.

One of the essential elements of the established review procedure is for the Secretariat to collect relevant information from Member States to prepare a Critical Review document for submission to the Expert Committee on Drug Dependence. The Director-General invites Member States to collaborate, as in the past, in this process by providing all pertinent information mentioned in the attached questionnaire[1] concerning the substances mentioned in items 1 to 3 above. The questionnaire does not include any questions about the groups of substances specified under item 4, since the required information is already being sought by the Secretary-General of the United Nations in his Circular Letter NAR/CL.4/1997.

Further clarification on any of the above items can be obtained from Psychotropic and Narcotic Drugs (PND), Division of Drug Management and Policies, WHO, Geneva, to which replies should be sent not later than *1 March 1998.*

GENEVA, 30 December 1997

Questionnaire for data collection for use by the World Health Organization and the Commission on Narcotic Drugs of the Economic and Social Council

Substance reported on:

1. Availability of the substance (registered, marketed, dispensed, etc.).
2. Extent of abuse of the substance.
3. Degree of seriousness of the public health and social problems[2] associated with abuse of the substance.
4. Number of seizures of the substance in the illicit traffic during the previous three years and the quantities involved.
5. Identification of the seized substance as of local or foreign manufacture and indication of any commercial markings.
6. Existence of clandestine laboratories manufacturing the substance.

II. United Nations Notifications

The U.S. Government has received two notifications from the Secretary General of the United Nations. The first notification (NAR/CL./1997, signed May 28, 1997), transmits under to Article 2, paragraph 1 of the Convention on Psychotropic Substances, 1971, a request from the Government of Spain to amend Schedules I and II of the Convention to include:

''(a) isomers, except where expressly excluded, of substances listed in those Schedules, whenever the existence of such isomers is possible;

''(b) esters and ethers of substances in those Schedules, except where included in another Schedule, whenever the existence of such esters or ethers is possible;

''(c) salts of those esters, ethers and isomers, under the conditions stated above, whenever the formation of such salts is possible;

''(d) a substance resulting from modification of the chemical structure of a substance already in Schedule I or Schedule II and which produces pharmacological effects similar to those produced by the original substance.''

The May 28, 1997, notification included as annexes, the original request from the Government of Spain, along with a questionnaire. A subsequent notification from the United

[1] For Ministries of Health only.

[2] Examples of public health and social problems are acute intoxication, accidents, work absenteeism, mortality, behaviour problems, criminality, etc.